Clonal hematopoiesis of indeterminate potential

Summary

Clonal hematopoiesis of indeterminate potential (MONDO:0100543) is a disease and 11 clinical trials. Top therapeutic interventions include mas-825. A subtype of clonal hematopoiesis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	clonal hematopoiesis of indeterminate potential
Mondo ID	MONDO:0100543
UMLS	C4761612
MedGen	1681237
GARD	0026273
Is cancer (heuristic)	no

Disease family

This is a subtype of clonal hematopoiesis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › premalignant hematological system disease › clonal hematopoiesis › clonal hematopoiesis of indeterminate potential

Related subtypes (1): age-related clonal hematopoiesis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	9
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07362966	PHASE4	NOT_YET_RECRUITING	Effect of Colchicine on Progression of Coronary Atherosclerosis in Patients With TET2-CHIP Variant
NCT06097663	PHASE2	COMPLETED	A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
NCT02958462	Not specified	RECRUITING	Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
NCT04102423	Not specified	RECRUITING	CHIP/CCUS Natural History Protocol
NCT05246813	Not specified	RECRUITING	Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP)
NCT05711173	Not specified	RECRUITING	Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)
NCT05969821	Not specified	NOT_YET_RECRUITING	Clonal Hematopoiesis of Immunological Significance
NCT06244069	Not specified	NOT_YET_RECRUITING	Clonal Hematopoiesis in Giant Cell Arteritis
NCT06870760	Not specified	RECRUITING	Pre-malignant States to Hematologic Malignancies in Firefighters
NCT07615023	Not specified	NOT_YET_RECRUITING	Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction
NCT04987268	Not specified	COMPLETED	CHIP and Residual Cardiovascular Event Tendency After Smoking Cessation

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MAS-825	3	1